{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:25:23Z","timestamp":1793921123532,"version":"4.8.0"},"reference-count":13,"publisher":"Innovative Healthcare Institute","issue":"4","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,24]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Immunotherapy is an established treatment for mismatch repair\u2013deficient (dMMR) colorectal cancer (CRC), driven by increased neoantigen formation and enhanced responsiveness to immune checkpoint inhibitors. Nous-209 is a polyvalent viral vector immunotherapy under investigation in combination with pembrolizumab in the NOUS-209-01 clinical trial (ClinicalTrials.gov Identifier: NCT04041310) in patients with dMMR CRC. Here, we report on a participant of the NOUS-209-01 trial who achieved a complete pathologic response and significant regression of colonic polyps following treatment with Nous-209 in combination with pembrolizumab and a right hemicolectomy. Genetic testing ruled out Lynch syndrome and mosaicism of Lynch syndrome\u2013associated genes. The patient remains relapse free and under active surveillance 18 months after treatment initiation. Three months after treatment ended, the patient experienced an episode of grade 3 immune-mediated colitis and this improved after infliximab treatment. The clinical and immunologic findings suggest the potential for Nous-209 immunotherapy, in combination with pembrolizumab, to induce regression of both malignant and premalignant colonic lesions. To our knowledge, this is the first report of an immunotherapy combination to reduce premalignant polyps in a patient who does not have Lynch syndrome.<\/jats:p>","DOI":"10.36401\/jipo-25-32","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:47:02Z","timestamp":1787838422000},"page":"124-129","source":"Crossref","is-referenced-by-count":0,"title":["Colonic Polyp Regression After Nous-209 Cancer Immunotherapy: A Clinical Trial Case Report"],"prefix":"10.36401","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4440-9583","authenticated-orcid":true,"given":"Marina","family":"Crespo-Cruz","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Oncology, University College London Hospitals NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Rodriguez-Justo","sequence":"additional","affiliation":[{"name":"Department of Histopathology, University College London Hospitals NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Humphries","sequence":"additional","affiliation":[{"name":"Department of Endoscopy, St Mark\u2019s the National Bowel Hospital and Academic Institute, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Plumb","sequence":"additional","affiliation":[{"name":"Department of Radiology, University College London Hospitals NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Antoniou","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, St Mark\u2019s the National Bowel Hospital and Academic Institute, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Monahan","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, St Mark\u2019s the National Bowel Hospital and Academic Institute, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Runswick","sequence":"additional","affiliation":[{"name":"Nouscom AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Capone","sequence":"additional","affiliation":[{"name":"Nouscom Srl, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Antonucci","sequence":"additional","affiliation":[{"name":"Nouscom Srl, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Garzia","sequence":"additional","affiliation":[{"name":"Nouscom Srl, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Micarelli","sequence":"additional","affiliation":[{"name":"Nouscom Srl, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Scarselli","sequence":"additional","affiliation":[{"name":"Nouscom Srl, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Morena","family":"D\u2019Alise","sequence":"additional","affiliation":[{"name":"Nouscom Srl, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Gogov","sequence":"additional","affiliation":[{"name":"Nouscom AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Keen","family":"Shiu","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, University College London Hospitals NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22027","reference":[{"key":"i2590-017X-9-4-124-b01","series-title":"Cell Rep","first-page":"857","article-title":"Genomic correlates of immune-cell infiltrates in colorectal carcinoma","volume":"15","author":"Giannakis","year":"2016","unstructured":"Giannakis M,Mu XJ,Shukla SA, et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep. 2016;15:857\u2013865."},{"key":"i2590-017X-9-4-124-b02","series-title":"Lancet Oncol","first-page":"1009","article-title":"Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis","volume":"18","author":"Turajlic","year":"2017","unstructured":"Turajlic S,Litchfield K,Xu H, et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 2017;18:1009\u20131021."},{"key":"i2590-017X-9-4-124-b03","series-title":"N Engl J Med","first-page":"2207","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andre","year":"2020","unstructured":"Andre T,Shiu KK,Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383:2207\u20132218."},{"key":"i2590-017X-9-4-124-b04","series-title":"Lancet","first-page":"383","article-title":"Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial","volume":"405","author":"Andre","year":"2025","unstructured":"Andre T,Elez E,Lenz HJ, et al. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial. Lancet. 2025;405:383\u2013395."},{"issue":"8 suppl 1","key":"i2590-017X-9-4-124-b05","series-title":"Cancer Res","first-page":"6427","article-title":"Abstract 6427: Nous-209 off-the-shelf neoantigen immunotherapy induces robust neoantigen T cell response with the potential to intercept cancer in Lynch syndrome carriers","volume":"85","author":"Willis","year":"2025","unstructured":"Willis J,D\u2019Alise AM,Hall MJ, et al. Abstract 6427: Nous-209 off-the-shelf neoantigen immunotherapy induces robust neoantigen T cell response with the potential to intercept cancer in Lynch syndrome carriers. Cancer Res. 2025;85(8 suppl 1):6427\u20136427."},{"key":"i2590-017X-9-4-124-b06","article-title":"NM_000059.4(BRCA2):c.1964C>G (p.Pro655Arg)","author":"ClinVar database","unstructured":"ClinVar database. NM_000059.4(BRCA2):c.1964C>G (p.Pro655Arg). Accessed Jun 30, 2025. www.ncbi.nlm.nih.gov\/clinvar\/variation\/37770\/"},{"key":"i2590-017X-9-4-124-b07","series-title":"Sci Transl Med","first-page":"eabo7604","article-title":"Adenoviral-based vaccine promotes neoantigen-specific CD8(+) T cell stemness and tumor rejection","volume":"14","author":"D\u2019Alise","year":"2022","unstructured":"D\u2019Alise AM,Brasu N,De Intinis C, et al. Adenoviral-based vaccine promotes neoantigen-specific CD8(+) T cell stemness and tumor rejection. Sci Transl Med. 2022;14:eabo7604."},{"key":"i2590-017X-9-4-124-b08","series-title":"Cancer Res","first-page":"3972","article-title":"A genetic vaccine encoding shared cancer neoantigens to treat tumors with microsatellite instability","volume":"80","author":"Leoni","year":"2020","unstructured":"Leoni G,D\u2019Alise AM,Cotugno G, et al. A genetic vaccine encoding shared cancer neoantigens to treat tumors with microsatellite instability. Cancer Res. 2020;80:3972\u20133982."},{"key":"i2590-017X-9-4-124-b09","series-title":"Mol Ther","first-page":"2412","article-title":"Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19","volume":"29","author":"Capone","year":"2021","unstructured":"Capone S,Raggioli A,Gentile M, et al. Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19. Mol Ther. 2021;29:2412\u20132423."},{"key":"i2590-017X-9-4-124-b10","series-title":"Cancer Discov","first-page":"1842","article-title":"Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade","volume":"10","author":"Zhang","year":"2020","unstructured":"Zhang Q,Luo J,Wu S, et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Discov. 2020;10:1842\u20131853."},{"key":"i2590-017X-9-4-124-b11","series-title":"Eur J Cancer","first-page":"113253","article-title":"Efficacy of PD-1 inhibitors for colorectal cancer and polyps in Lynch syndrome patients","volume":"192","author":"Yu","year":"2023","unstructured":"Yu JH,Xiao BY,Tang JH, et al. Efficacy of PD-1 inhibitors for colorectal cancer and polyps in Lynch syndrome patients. Eur J Cancer. 2023;192:113253."},{"key":"i2590-017X-9-4-124-b12","series-title":"Nat Med","first-page":"2458","article-title":"Neoplasia risk in patients with Lynch syndrome treated with immune checkpoint blockade","volume":"29","author":"Harrold","year":"2023","unstructured":"Harrold EC,Foote MB,Rousseau B, et al. Neoplasia risk in patients with Lynch syndrome treated with immune checkpoint blockade. Nat Med. 2023;29:2458\u20132463."},{"key":"i2590-017X-9-4-124-b13","series-title":"Gastroenterology","first-page":"787","article-title":"Genomic landscape of Lynch syndrome colorectal neoplasia identifies shared mutated neoantigens for immunoprevention","volume":"166","author":"Bolivar","year":"2024","unstructured":"Bolivar AM,Duzagac F,Deng N, et al. Genomic landscape of Lynch syndrome colorectal neoplasia identifies shared mutated neoantigens for immunoprevention. Gastroenterology. 2024;166:787\u2013801 e11."}],"container-title":["Journal of Immunotherapy and Precision Oncology"],"original-title":[],"link":[{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/view\/journals\/jipo\/9\/4\/article-p124.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/downloadpdf\/journals\/jipo\/9\/4\/article-p124.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/downloadpdf\/journals\/jipo\/9\/4\/article-p124.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:35:17Z","timestamp":1793918117000},"score":1,"resource":{"primary":{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/view\/journals\/jipo\/9\/4\/article-p124.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":13,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.36401\/jipo-25-32","relation":{},"ISSN":["2590-017X","2666-2345"],"issn-type":[{"value":"2590-017X","type":"electronic"},{"value":"2666-2345","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,24]]}}}